NCT04656561Phase 2Completed

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

Study sponsor: Annexon, Inc. · ANNX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-03-28Actual
Enrollment · participants270Actual
Source updated2026-10-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: GA lesion growth rate Description: Change in GA lesion area as assessed by fundus autofluorescence (FAF) Time frame: Baseline to Month 12. After: Measure: Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area Description: GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area. A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups. The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality. A random intercept for participant ID and a random slope for timepoint are included to account for repeated measurements for participants. The GA lesion area was analyzed as reported (that is, not transformed). Time frame: Baseline to Month 12.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview